Bookbuilding IPO | ₹52 Cr | Listed at NSE SME | Thu, May 21, 2026 - Mon, May 25, 2026
Bio Medica Laboratories IPO is a book build issue of ₹52.43 crores. The issue is a combination of fresh issue of 0.34 crore shares aggregating to ₹47.19 crores and offer for sale of 0.04 crore shares aggregating to ₹5.24 crores.
Bio Medica Laboratories IPO bidding started from May 21, 2026 and ended on May 25, 2026. The allotment for Bio Medica Laboratories IPO was finalized on May 26, 2026. The shares got listed on the NSE SME on May 29, 2026.
Bio Medica Laboratories IPO is set final issue price at ₹139 per share. The lot size for an application is 1,000 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,78,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹4,17,000.
Narnolia Financial Services Ltd. is the book running lead manager and Skyline Financial Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Prabhat Financial Services Ltd.
Refer to Bio Medica Laboratories IPO RHP for detailed Information.
IPO Open
Thu, May 21, 2026
IPO Close
Mon, May 25, 2026
Issue Price
₹139 per share
Market Cap (Pre-IPO)
₹174.79 Cr
| IPO Date | 21 to 25 May, 2026 |
| Listed on | Fri, May 29, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹132 to ₹139 |
| Issue Price | ₹139 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 37,72,000 shares (agg. up to ₹52 Cr) |
| Reserved for Market Maker | 1,89,000 shares Prabhat Financial Services Ltd. (agg. up to ₹3 Cr) |
| Fresh Issue (Ex Market Maker) | 32,06,000 shares (agg. up to ₹45 Cr) |
| Offer for Sale | 3,77,000 shares of ₹10 (agg. up to ₹5 Cr) |
| Net Offered to Public | 35,83,000 shares (agg. up to ₹50 Cr) |
| Share Holding Pre Issue | 91,80,001 shares |
| Share Holding Post Issue | 1,25,75,001 shares |
| / NSE Symbol | / BMLL |
| ISIN | INE1BKA01015 |
Bio Medica Laboratories IPO comprises a total issue size of 37,72,000 shares. The net offer to the public is 35,83,000 shares, after excluding 1,89,000 shares allotted on a firm basis. Of the Net offer 36,000 (1.00%) are allocated to QIB, 17,55,000 (48.98%) allocated to NII 17,92,000 (50.01%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 36,000 | 1.00% | 0.95% |
| NII (HNI) Shares Offered | 17,55,000 | 48.98% | 46.53% |
| − bNII > ₹10L | 11,70,000 | 31.02% | |
| − sNII < ₹10L | 5,85,000 | 15.51% | |
| Retail Shares Offered | 17,92,000 | 50.01% | 47.51% |
| Firm Reservations | |||
| Market Maker Shares Offered | 1,89,000 | 5.01% | |
| Total Shares Offered | 37,72,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 2,000 | ₹2,78,000 |
| Individual investors (IND) (Max) | 2 | 2,000 | ₹2,78,000 |
| S-HNI (Min) | 3 | 3,000 | ₹4,17,000 |
| S-HNI (Max) | 7 | 7,000 | ₹9,73,000 |
| B-HNI (Min) | 8 | 8,000 | ₹11,12,000 |
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.
Product portfolio:
It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications.
The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh.
It has two manufacturing facilities in Indore, Madhya Pradesh.
Competitive Strengths
| Period Ended | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
| Amount in ₹ Crore | ||||
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹42.23 (-0.14%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹193.00 (-1.28%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹255.40 (-4.99%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹253.70 (-1.11%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹99.40 (+0.00%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹233.95 (+1.72%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹80.00 (+0.00%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹292.60 (+2.49%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹256.10 (-1.50%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹623.80 (+2.01%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,009.00 (+2.47%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.68 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,374.20 (+0.53%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹160.12 (+2.23%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.90 (+0.13%) |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment of loan | 6.50 |
| 2 | Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 28.50 |
| 3 | General Corporate Purposes | 7.05 |
| 4 | Issue Expense | 5.14 |
| Total | 47.19 |
| KPI | Nov 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 54.41% | 99.59% |
| ROCE | 23.22% | 48.20% |
| Debt/Equity | 2.23 | 1.02 |
| RoNW | 54.41% | 99.59% |
| PAT Margin | 30.35% | 25.64% |
| EBITDA Margin | 47.11% | 39.83% |
| Price to Book Value | 8.66 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 10.67 | 10.33 |
| P/E (x) | 13.03 | 13.45 |
| Promoter Holding | 96.84% | |
| Market Cap | ₹174.79 Cr. |
The Bio Medica Laboratories IPO IPO subscription status. Full data available on IPOMatrix.com.
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Applications |
|---|---|---|---|---|
| Total | 2.23 | 35,83,000 | 80,03,000 | 3,036 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead manager(s) fees | 1.00 |
| 2 | Underwriting commission | 2.62 |
| 3 | Brokerage, selling commission and upload fees | 0.02 |
| 4 | Registrars to the issue | 0.01 |
| 5 | Legal Advisors | 0.06 |
| 6 | Advertising expenses | 0.07 |
| 7 | Regulators including stock exchanges | 0.10 |
| 8 | Printing and Distribution of Issue Stationary | 0.01 |
| 9 | Others, if any (Market Maker fees, Peer Review Auditor, Selling and Distribution Expenses, Marketing Expenses and other misc. expenses) | 1.25 |
| Total | 5.14 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹139.00 |
| Open | ₹111.20 |
| Low | ₹105.65 |
| High | ₹116.75 |
| Last Trade | ₹115.80 |
Lead Manager Reports
Bio Medica Laboratories IPO is a SME IPO of 37,72,000 equity shares of the face value of ₹10 aggregating up to ₹52 Crores. The issue is priced at ₹139 per share. The minimum order quantity is 1000.
The IPO opens on Thu, May 21, 2026, and closes on Mon, May 25, 2026.
Skyline Financial Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Bio Medica Laboratories IPO using UPI as a payment gateway. Zerodha customers can apply in Bio Medica Laboratories IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Bio Medica Laboratories IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Bio Medica Laboratories IPO opens on Thu, May 21, 2026 and closes on Mon, May 25, 2026.
Bio Medica Laboratories IPO lot size is 1000, and the minimum amount required for application is ₹2,78,000, with 2 lots being the minimum application size.
You can apply in Bio Medica Laboratories IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Bio Medica Laboratories IPO will be done on Tuesday, May 26, 2026, and the allotted shares will be credited to your demat account by Wed, May 27, 2026. Check the Bio Medica Laboratories IPO allotment status.
The Bio Medica Laboratories IPO listing date is on Fri, May 29, 2026.
